The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net income | 736,800 | 585,300 | 755,600 | 413,900 |
| Depreciation expense | 89,700 | 83,200 | 72,800 | 67,000 |
| Amortization expense | 157,700 | 155,900 | 152,400 | 152,000 |
| Change in fair value of business acquisition liabilities | 19,000 | - | - | - |
| Deferred income taxes | 36,000 | -82,000 | -13,800 | -117,700 |
| Business exit related impairments | 45,600 | - | - | - |
| Vms trade name and other asset impairments-VMSTradename | 0 | 357,100 | - | - |
| Flawless impairment | - | - | 0 | 411,000 |
| Vms trade name and other asset impairments-Flawless Tradename | - | 0 | - | - |
| Loss on sale of vitamin business | -58,500 | - | - | - |
| Equity in net earnings of affiliates | 7,900 | 9,100 | 8,700 | 12,300 |
| Distributions from unconsolidated affiliates | 8,800 | 8,900 | 9,500 | 8,700 |
| Non-cash compensation expense | 58,000 | 59,200 | 63,600 | 32,300 |
| Asset impairment charge and other asset write-offs | 10,100 | 12,100 | 8,900 | 2,400 |
| Gain on sale of assets | - | - | - | 0 |
| Other | 6,700 | 6,200 | 400 | 3,200 |
| Subtotal | 1,205,600 | - | - | - |
| Accounts receivable | -39,400 | 81,500 | 97,400 | 5,300 |
| Inventories | -56,100 | -2,000 | -38,500 | 92,800 |
| Other current assets | -1,200 | 500 | -10,400 | -2,500 |
| Accounts payable | 2,400 | 98,600 | - | - |
| Accounts payable and accrued expenses | - | - | 55,200 | 39,900 |
| Accrued expenses | -60,900 | -1,100 | - | - |
| Income taxes payable | -5,100 | -7,100 | -1,800 | 14,400 |
| Other operating assets and liabilities, net | 23,300 | 18,600 | 14,200 | 27,600 |
| Change in working capital | -9,800 | - | - | - |
| Net cash provided by operating activities | 1,215,400 | 1,156,200 | 1,030,600 | 885,200 |
| Additions to property, plant and equipment | 122,400 | 179,800 | 223,500 | 178,800 |
| Acquisitions | 656,000 | 19,900 | 0 | 546,800 |
| Proceeds from sale of passport | 0 | 6,600 | - | 0 |
| Proceeds from sale of vitamin business | 160,300 | - | - | - |
| Other | -1,200 | -9,800 | 10,800 | 3,000 |
| Net cash used in investing activities | -616,900 | -183,300 | -234,300 | -728,600 |
| Long-term debt borrowings | - | 0 | 0 | 998,800 |
| Repayments of long-term debt | 0 | 204,600 | 200,000 | 700,000 |
| Short-term debt (repayments), net of borrowings | 0 | -3,600 | -70,600 | -178,900 |
| Proceeds from stock options exercised | 35,600 | 142,900 | 111,700 | 26,200 |
| Payment of cash dividends | 287,200 | 277,000 | 266,500 | 255,000 |
| Purchase of treasury stock | 900,000 | 0 | 300,100 | 0 |
| Payment of business acquisition liabilities | - | - | - | 0 |
| Payment of business acquisition liability | -5,900 | - | - | - |
| Deferred financing and other | - | 1,100 | 100 | 12,000 |
| Other | -4,900 | - | - | - |
| Net cash used in financing activities | -1,162,400 | -343,400 | -725,600 | -120,900 |
| Effect of exchange rate changes on cash and cash equivalents | 8,800 | -9,900 | 3,500 | -6,000 |
| Net change in cash and cash equivalents | -555,100 | 619,600 | 74,200 | 29,700 |
| Cash and cash equivalents at beginning of period | 964,100 | 344,500 | 270,300 | 240,600 |
| Cash and cash equivalents at end of period | 409,000 | 964,100 | 344,500 | 270,300 |
CHURCH & DWIGHT CO INC DE (CHD)
CHURCH & DWIGHT CO INC DE (CHD)